Notes from Nathan
May is Annual Conference month here at NewYorkBIO, and, as we hang the signs and polish the bannisters in our final preparations for the 2016 NewYorkBIO Annual Conference, it's becoming clear that this is shaping up to be our best event yet. To get you ready, this edition of NewYorkBIO News is packed with useful Conference information, but before we look forward to all the programming, I want to look back on our success with the Spring legislative activities.
Our Fly-In to Washington, DC, was very successful, with our members meeting 16 of our Members of Congress and two Senators to discuss all of our federal issues. At Albany's Advocacy Day and Legislative Fly-In events, NewYorkBIO members joined NewYorkBIO staff in expressing concerns about important legislation. Thanks to these efforts and NewYorkBIO's strong advocacy, we successfully protected our constituents from draconian price control legislation, which was ultimately stricken from the Governor's budget. Of course, Albany is facing a turbulent period, with powerful positions split between houses and political parties. In spite of the unsettled political atmosphere, NewYorkBIO remains attentive and committed to the legislative concerns of our membership.
We'll see you at the Conference!
NewYorkBIO and BIO Business Solutions®, BIO's cost-savings program, have announced a new partnership with UniFirst Corporation, bringing our members a wide selection of uniforms, lab coats, and other garments, along with facility service products and microfiber cleaning supplies at 30-50% off. UniFirst rental programs outfit employees, provide scheduled pickups and deliveries, and handle hygienic cleanings, garment repairs, and replacements.
The UniFirst partnership also extends to offerings from UniClean, a division of UniFirst that provides specialized cleanroom and controlled environment garment-related service
2016 NewYorkBIO Annual Conference,
SELECT PROGRAM HIGHLIGHTS
Wall Street Unplugged: Management's Guide to Wall Street & the Capital Markets
This panel is targeted to CEOs, CFOs and IR managers at private and public small- to- mid-cap life science companies to gain better insight into Wall Street and the Capital Markets, and to enable them to learn to maximize their communication with the investment community. We will moderate a panel representing institutional investors, sell-side analysts, investment bankers and other leading industry members to discuss relevant topics within the financial and biotech industry. According to Nathan Tinker, "This panel offers a unique opportunity for senior management to interact directly with the Wall Street community."
From Bugs to Drugs: Exploring the Human Microbiome for Health and Disease
In this science panel, we will discuss to the developing world of the human microbiome and how it impacts health and disease. The panel of professionals, coming from academia and industry, will review cutting edge science and showcase how better understanding the microbiome could provide new approaches to treating not only diseases of the gut, but also diabetes, obesity and neuropsychiatric disorders.
Funding Tips for New York Biotech Startups
This presentation is a Q & A session designed to provide NY Biotech Startups with useful tips on how to prepare to meet and interact with members of the New York Biotech investment community. The panelists will describe their role in NY Biotech funding from various viewpoints and describe the information they want from prospective fund seekers. Please join us and share in the opportunity of speaking with these knowledgeable panelists. According to Nathan Tinker, "Whether you are looking
for funding or hoping to be part of the next big thing, the information you gather here will prove invaluable."
Business Development Leaders to Judge PitchFest
Senior business development experts from Merck, Pizer, Eli Lilly, Sanofi, and Novartis are among the distinguished panel of judges featured at PitchFest. At PitchFest, each entrepreneur will give a 15-minute pitch to an investor panel. This will be followed by 5 minutes of Q&A and 5 minutes of non-rebuttal feedback from the panel. Pitches will be evaluated and scored on a range of important business and scientific criteria. Leading scorers and winners will be announced during the keynote program later in the day. This popular event, featuring over 40 companies, on Wednesday, May 11th.
Celgene CEO Mark J. Alles to Keynote Conference Luncheon
Celgene CEO Mark Alles will deliver the Keynote address, "Medical Innovation and Health: Today's Age of great Hope, Challenges, and Opportunities" on Thursday, May 12th. Mark J. Alles serves as Celgene's Chief Executive Officer. He assumed the role on March 1, 2016. Previously he served as President and Chief Operating Officer. Mr. Alles served as Executive Vice President and Global Head of Hematology and Oncology from December 2012 until July 2014, following his promotion to Executive Vice President and Chief Commercial Officer in February 2012.
Mr. Alles joined Celgene in April 2004 and served as Vice President, Global Marketing until March 2009 when he became President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011.
Mr. Alles previously served as Vice President for the U.S. Oncology Business Unit of Aventis Pharmaceuticals and in other commercial sales and marketing management roles over an 11-year period with Aventis. After earning his B.S. degree from Lock Haven University of Pennsylvania and serving as a Captain in the United States Marine Corps, Mr. Alles began his 29-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. Mr. Alles is a member of the Celgene Board of Directors, the Trustees for the Healthcare Institute of New Jersey (HINJ), the Board of the Biotechnology Innovation Organization (BIO), and the Board of Gilda's Club NYC, a not-for-profit organization helping the families of people living with cancer.
New York Legislative Update
NEW YORK STATE UPDATE
NewYorkBIO is hard at work in Albany on over a dozen major legislative priorities to strengthen and support biosciences across the state.
- NewYorkBIO strongly opposes the efforts to mandate price controls on Biopharmaceutical products. As one of the largest bioscience sectors in the country, New York bioscience could be crippled by this legislation.
- Legislation providing for the regulation of genetically engineered products, A.617B/S.485B, is under consideration in the Assembly Codes Committee. This legislation would impose a set of new labeling requirements on products that contain food that has been modified by modern genetic engineering techniques. NewYorkBIO strongly opposes this unnecessary and expensive legislation, which threatens to undermine New York's leadership in the field of biotechnology.
- NewYorkBIO supports A.8648/S.6311, legislation promoting patient safety with regard to biosimilars. NewYorkBIO believes that certain safeguards should guide the setting of parameters for safe substitution of interchangeable biologics under state law, in order to ensure transparency between patients and their treatment teams.
Despite this being an election year, there is still a lot of bioscience-related activity in Washington DC.
- NewYorkBIO, along with BIO, the Coalition for Safe and Affordable Food, and 18 other state life science associations, joined forces in support of the H.R. 1599, the Safe and Accurate Food Labeling Act. This bipartisan legislation will ensure that food labeling in the United States is uniform and science-based. The proposed legislation also would improve clarity for foods carrying a GMO-free label and provide uniform rules by creating a national certification program for foods that have been produced without bioengineering.
- We also worked closely with BIO to in support of H.R. 4139, the Fostering Innovation Act. The Fostering Innovation Act would support the growth of emerging biotechs by reducing the cost of burdensome regulations. Specifically, the bill would create a targeted five-year exemption from Sarbanes-Oxley (SOX) Section 404(b) for JOBS Act companies that are still pre-revenue when the IPO On-Ramp expires. The Fostering Innovation Act represents a move away from one-size-fits-all compliance burdens, and we believe it will sustain the growth of the biotech industry in New York and support the search for the next generation of medical breakthroughs.
|The NewYorkBIO delegation meets with Representative Nydia Velasquez during the BIO Fly-In 2016
Welcome New Members
A special welcome and thank you to our newest
American Laboratory Trading
Applied Biological Laboratories
Aset Therapeutics LLC
August Research LLC
Efferent Labs, Inc.
Explorium Capital LLC
Frommer Lawrence & Haug LLP
Highline Therapeutics, Inc.
Kyras Therapeutics Inc.
Merck & Co Inc.
Mirna Analytics, LLC
NomoCan Pharmaceuticals LLC
Pepper Hamilton LLP
RespireRx Pharmaceuticals Inc.
Syndax Pharmaceuticals, Inc.
Synthetic Genomics: SGI-DNA
US Specialty Formulations LLC
Xaleron Pharmaceuticals, Inc.
Breakfast with Thong Q. Le
Wednesday, May 18 @ 7:30 AM
|NewYorkBIO Member News
If you have news to share with our 20,000+ subscribers, please send notes or releases to
AbbVie announced that it will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T) currently in registrational trials for small cell lung cancer (SCLC).
Albert Einstein College of Medicine of Yeshiva University
Albert Einstein College of Medicine announced that it has received a $3.6 million NIH grant to investigate how APP is processed in the brain.
Applied DNA Sciences, Inc.
Applied DNA Sciences, Inc., has appointed Bob Miglani as Chief of Business Development.
Astellas announced that Joseph Fleishaker, Ph.D., has been named vice president, Clinical Pharmacology and Exploratory Development.
Bristol Myers Squibb announced that it has completed the previously announced planned acquisition of Padlock Therapeutics, Inc.
Cellectis announced that it
has entered into a supply and license agreement with Takara Bio Inc. for recombinant human fibronectin fragment RetroNectin®.
Chembio Diagnostic Systems Inc.
Chembio Diagnostics, Inc.
announced the status of its plans with Bio-Manguinhos/Fiocruz to obtain regulatory approval and to introduce a POC diagnostic test for Zika virus in Brazil.
Children's Tumor Foundation
launched a new consortium for schwannomatosis, the rarest and least studied form of neurofibromatosis.
City University Of New York
Neuroscience Collaborative Professor Jon Horvitz won the NIH High Priority, Short-Term Project Award for the 2015-2016 academic year.
Clean Harbors Environmental Services
Clean Harbors Environmental Services announced
the appointment of Lauren C. States to the Company's Board of Directors.
Cold Spring Harbor
Cold Spring Harbor Laboratory announced the Center for Therapeutics Research (CTR) project, a new $75 million initiative to apply the Laboratory's biomedical expertise toward advancing therapeutics for genetic diseases.
Columbia Technology Ventures, Columbia University
Conner Strong & Buckelew
Conner Strong & Buckelew
announced that it has formed a strategic alliance with Century Equity Partners to accelerate the firm's expansion strategy.
Efferent Labs, Inc.
Sensor technology from Efferent Labs was featured in a news story on WGRZ.
Eli Lilly and Company
Eli Lilly and Company announced
that Taltz® injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis is now available by prescription order through a contracted network of specialty pharmacies in the United States.
Enumeral Biomedical Corp.
Enumeral Biomedical Holdings, Inc. announced t
hat it has entered into a License and Transfer Agreement with Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH.
Gilda's Club welcomed Laura Bartlett as the GCNYC Board Chair
Highline Therapeutics, Inc.
Versant Ventures announced promotions and an addition to its investment team.
Intensity Therapeutics, Inc
SalvaRx announced its investment in US-based Intensity Therapeutics Inc.
International AIDS Vaccine Initiative
IAVI announced that a
research team has now found that the right precursor cells for one kind of HIV broadly neutralizing antibody are present in most people, and has described the design of an HIV vaccine germline-targeting immunogen capable of binding those B cells.
Johnson & Johnson Innovation Center
Robert G. Urban has been appointed Global Head, Johnson & Johnson Innovation.
Merck & Co Inc.
Merck announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the company's anti-PD-1 therapy, for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma.
MetaStat, Inc., announced the appointment of Jerome B. Zeldis, M.D., Ph.D. to serve as Vice Chairman of the company's Board of Directors.
Ophthotech Corporation announced t
he appointment of Carmen A. Puliafito, MD, MBA, as Chief of Strategic Development.
Pfizer Inc. and IBM announced a research collaboration to develop innovative remote monitoring solutions aimed at transforming how clinicians deliver care to patients suffering from Parkinson's disease.
Pulmokine announced it has been awarded a Stage B Vascular Interventions and Therapeutic Advances contract from the National Heart, Lung, and Blood Institute, a division of the National
Institutes of Health.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Inc.
announced that it has entered into a licensing agreement under which Regeneron will use MedImmune's pyrrolobenzodiazepine (PBD)-based warhead and linker technology to produce antibody- drug conjugates (ADCs) as potential cancer treatments.
that the U.S. Food and Drug Administration granted accelerated approval to Venclexta™ for the treatment of people with chronic lymphocytic leukemia with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
The Rockefeller University
The Rockefeller University
announced that its Board of Trustees has elected Richard P. Lifton to be the 11th president of the university, effective September 1, 2016.
Royalty Pharma Management, LLC
UCLA and Royalty Pharma announced that UCLA has sold its royalty interest connected with a leading prostate cancer medication, Xtandi.
SUNY Downstate Medical Center
Research led by SUNY Downstate Medical Center has identified a brain receptor that appears to initiate adolescent synaptic pruning, a process believed necessary for learning, but one that appears to go awry in both autism and schizophrenia.
Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc.,
announced that it has priced its initial public offering of 4,400,000 shares of its common stock at a public offering price of $12.00 per share, for an aggregate offering of $52.8 million, before underwriting discounts, commissions and expenses.
Researchers from Synthetic Genomics Inc. and the J. Craig Venter Institute announced the design and construction of the first minimal synthetic bacterial cell, JCVI-syn3.0.
University of Rochester Medical Center
University of Rochester Medical Center researchers have uncovered a new mechanism of bone erosion and a possible biomarker for rheumatoid arthritis.
Weill Cornell Graduate School of Medical Sciences
Weill Cornell Medicine has established the Cardiovascular Research Institute to expand and enhance the institution's basic and translational research activities. Dr. Geoffrey Pitt, a leading cardiologist and scientist, will direct the institute.